Glossary · Treatments

Duavee (CE/bazedoxifene)

Also called: CE/bazedoxifene, Conjugated estrogens/bazedoxifene.

Definition: Duavee combines conjugated equine estrogens with the SERM bazedoxifene as a tissue-selective estrogen complex. The bazedoxifene component provides endometrial protection without traditional progestogen. It is FDA-approved for vasomotor symptoms and osteoporosis prevention in women with an intact uterus.

Detailed definition

Duavee is a tissue-selective estrogen complex (TSEC) combining 0.45 mg conjugated estrogens with 20 mg bazedoxifene in a single oral tablet. Bazedoxifene is a SERM that acts as an estrogen-receptor antagonist in the endometrium, providing endometrial protection and eliminating the need for a separate progestogen in women with an intact uterus. FDA-approved indications are moderate-to-severe vasomotor symptoms and osteoporosis prevention. Compared to traditional CEE+MPA combinations, Duavee may have a more favorable breast profile (no progestin) and avoids the side effects some women experience on progestogens (mood changes, breast tenderness). It still carries the oral-route VTE risk of CEE.

Why it matters in menopause

For women with a uterus who do not tolerate any progestogen well, Duavee is a useful single-pill alternative — although the underlying estrogen is conjugated equine estrogens rather than bioidentical estradiol, which is a trade-off relative to transdermal estradiol plus micronized progesterone.

Sources

External references: Wikipedia.

← Back to full glossary